Oak Park, IL

Illinois Retina Associates, S.C

Macular Edema

Uveitis

Posterior Uveitis

Edema

Pars Planitis

Intermediate Uveitis

Panuveitis

Anterior Uveitis

Diabetic Retinopathy

Retinal Diseases

Bevacizumab

Pemafibrate

Fluocinolone Acetonide

Jaeb Center for Health Research

Alimera Sciences

Clearside Biomedical

condition

allSponsorName

CBCC Global Research

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

A study to evaluate the safety and efficacy of YUTIQ® 0.18 mg intravitreal implant for the management of chronic non-infectious posterior segment uveitis (intraocular inflammation) that has responded to previous steroid therapy.

Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis

Illinois Retina Associates, S.C | Oak Park, IL

Site insights

Work at this site?

Active trials

Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis

Trial sponsors